PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023
PaxMedica, a clinical stage biopharmaceutical company, has announced its Gold Sponsorship of The BRAIN Foundation’s prestigious Synchrony Symposia 2023. This event is globally recognized for its role in advancing translational research in autism and related neurodevelopmental disorders. By sponsoring this symposium, PaxMedica aims to foster collaboration, innovation, and the dissemination of groundbreaking research in the field.
The Synchrony Symposia brings together leading scientists, clinicians, biotech and pharmaceutical companies, venture partners, and community stakeholders to promote scientific advancements that can enhance the well-being and quality of life for individuals affected by Autism Spectrum Disorder (ASD). PaxMedica’s commitment to this critical cause aligns seamlessly with the symposium’s mission.
As the only publicly traded U.S. company primarily focused on autism, PaxMedica is dedicated to developing innovative therapies that address the unmet medical needs of individuals with ASD. The company’s Chairman and CEO, Howard Weisman, expressed his excitement about supporting The BRAIN Foundation’s Synchrony Symposia, stating, “PaxMedica is deeply committed to improving the lives of individuals with autism and their families, and we are excited to contribute to this vital initiative.”
The symposium offers a platform for attendees to engage in interdisciplinary discussions, gain insights from leading experts, and participate in research presentations, clinical roundtables, mentor-mentee sessions, and more. PaxMedica’s Gold Sponsorship demonstrates its unwavering dedication to supporting research that can lead to meaningful advancements in the understanding and treatment of neurodevelopmental disorders.
PaxMedica is a clinical stage biopharmaceutical company focused on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Their primary focus is on Autism Spectrum Disorder (ASD) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), both of which are debilitating conditions affecting individuals physically and cognitively.
One of PaxMedica’s key programs is the development and testing of PAX-101, an intravenous formulation of suramin, for the treatment of ASD. Additionally, the company aims to advance the clinical understanding of using this agent against other disorders such as ME/CFS.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts on PaxMedica’s website. The company also maintains an active presence on social media platforms like Twitter, YouTube, and LinkedIn.
While PaxMedica continues to focus on its clinical program and anticipated data announcements, it acknowledges the inherent risks and uncertainties associated with drug development. The company remains committed to its mission of improving the lives of individuals with neurodevelopmental disorders and encourages investors to review the factors that may affect its future results, as outlined in its regulatory filings.
PaxMedica’s participation in The BRAIN Foundation’s Synchrony Symposia highlights its dedication to advancing scientific knowledge and collaboration in the field of autism research. By supporting this vital initiative, PaxMedica is making significant strides towards improving the lives of individuals with autism and their families.